CJC-1295 (without DAC) combined with Ipamorelin is a research peptide blend widely studied in laboratory and preclinical endocrinology models. Both compounds are examined for their role in growth hormone (GH) signaling through distinct biological pathways.
Veltrix Peptides supplies this combination strictly for controlled scientific and laboratory research.
Research Focus
In experimental settings, CJC-1295 (No DAC) + Ipamorelin has been studied in relation to:
Growth hormone secretion models
Endocrine signaling pathway research
IGF-1 regulatory investigations
Cellular growth and repair studies
Metabolic and recovery-related research models
The combination is often analyzed for its potential synergistic interaction in GH-related laboratory studies.
All investigations remain preclinical and are conducted under controlled research conditions.
Mechanism of Study
Within scientific literature:
CJC-1295 (No DAC) is a growth hormone-releasing hormone (GHRH) analog studied for its ability to stimulate pulsatile GH release.
Ipamorelin is a growth hormone secretagogue studied for its interaction with the ghrelin (GHSR-1a) receptor.
Together, they are researched for their combined influence on endogenous GH signaling pathways in laboratory environments.
Product Specifications
Compounds: CJC-1295 (No DAC) + Ipamorelin
Form: Lyophilized peptide blend
Quantity: 10mg total per vial
Purity: ≥99% (independently tested)
Documentation: Certificate of Analysis (COA) available
Storage (unmixed): Store in a cool, dry environment away from light
Intended Use: Laboratory research only
Stability & Storage
Store lyophilized blend in a cool, dry place
After reconstitution, refrigerate at 2–8°C
Recommended stability: Up to 60 days after reconstitution under proper laboratory storage conditions
Quality Assurance
Each batch is independently tested to verify identity and purity, ensuring consistent research-grade quality standards.
